08:31 AM EDT, 06/20/2025 (MT Newswires) -- Aptose Biosciences ( APTOF ) on Friday said it secured a new loan of up to US$8.5 million with Hanmi Pharmaceutical to advance clinical development of tuspetinib-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML).

The clinical-stage precision oncology company said data to date reveal promising antileukemic activity and safety across diverse AML populations.

Aptose's share price gained 7.7% on Thursday to $1.26 on the TSX.